SkylineDx's Innovative Contribution to Cancer Diagnosis
SkylineDx has made a significant impact in the field of molecular diagnostics, particularly in oncology. The company's latest research centers around a groundbreaking publication focusing on the SKY92 gene expression profiling test. This innovative tool aims to redefine the understanding of ultra-high-risk multiple myeloma, a complex disease characterized by its variability among patients. Through this publication, which details how SKY92 can be paired with fluorescence in situ hybridization (FISH), SkylineDx highlights its commitment to enhancing cancer diagnostics.
Understanding Multiple Myeloma and the SKY92 Test
Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow. It is known for its heterogeneity, meaning that its progression and aggressiveness can vary greatly among individuals. This variability poses a challenge for accurate diagnosis and treatment. The SKY92 test introduces an effective means of assessing the biological behavior of multiple myeloma through the analysis of 92 specific genes.
The Importance of Gene Expression Profiling
In its recent study, SkylineDx emphasizes the pivotal role that gene expression profiling plays in identifying patients with ultra-high-risk multiple myeloma, particularly in newly diagnosed and relapsed cases. The prospective real-world evidence study has revealed that integrating SKY92 with FISH provides a more precise risk stratification method than what has previously existed in clinical practice.
Improved Treatment Strategies for Patients
By using this combined approach, healthcare professionals can tailor treatment plans more effectively, ensuring that high-risk cases are recognized and managed appropriately. Accurate risk assessment through the SKY92 test allows for risk-adapted treatment strategies, ultimately aiming to improve patient outcomes in a disease where treatment responses can be unpredictable.
Expert Insights and Future Directions
Professor Martin Kortüm, a key figure behind the research, shared insights into the practical application of the SKY92 test in clinical settings. According to him, the test has demonstrated substantial reliability in identifying high-risk patients whose profiles might not be made apparent through traditional FISH methods. This adaptation could lead to the identification of patients who otherwise might miss out on vital interventions.
SkylineDx's Chief Scientific Officer, Jvalini Dwarkasing, echoed this sentiment by emphasizing the collaborative effort that produced these vital research findings, solidifying the company’s role at the forefront of precision medicine. The development solidifies SkylineDx's aim to continuously explore and innovate diagnostic tools that enhance patient care.
The Role of MMprofiler in Understanding Myeloma
MMprofiler, in conjunction with the SKY92 biomarker, is designed to deepen the understanding of multiple myeloma's biological diversity. By measuring gene activity in malignant plasma cells, MMprofiler aims to determine how aggressive the myeloma is. For patients diagnosed with high-risk disease, the implications are clear: these individuals may need more intensive therapy options to combat their illness effectively. The test is CE-IVD registered in Europe and is available from SkylineDx's CAP/CLIA certified laboratory in the USA.
About SkylineDx
SkylineDx is dedicated to the research and development of molecular diagnostics that bridge the gap between academic discoveries and practical, clinically relevant diagnostic tools. From their headquarters in Rotterdam and their laboratory in San Diego, California, they strive to create solutions that facilitate individualized treatment plans based on accurate disease status and patient response predictions.
Frequently Asked Questions
What is the SKY92 test?
The SKY92 test is a gene expression profiling test that measures the activity of 92 genes in plasma cells to determine the aggressiveness of multiple myeloma.
How does SKY92 improve multiple myeloma treatment?
By combining SKY92 with FISH, clinicians can achieve more precise risk stratification, enabling more tailored and effective treatment plans for patients.
What is MMprofiler?
MMprofiler is a molecular diagnostic test that enhances insights into multiple myeloma by evaluating gene expression and assessing disease aggressiveness.
Where is SkylineDx headquartered?
SkylineDx is headquartered in Rotterdam, the Netherlands, with a laboratory in San Diego, California, USA.
Is the SKY92 test available for use?
Yes, the SKY92 test is currently available as a laboratory developed test (LDT) from SkylineDx's certified lab.
